Skip to main content
. 2026 Mar 6;18(5):848. doi: 10.3390/cancers18050848
ADT Androgen Deprivation Therapy
AE Adverse Events
ARPI Androgen Receptor Pathway Inhibitor 
BC Biochemical Control
BFS Biochemical Failure-free Survival
CBCT Cone-Beam Computed Tomography
CRPC Castration-Resistant Prostate Cancer
CTCAE Common Terminology Criteria for Adverse Events
CTV Clinical Target Volume
ECOG Eastern Cooperative Oncology Group performance status
EBRT External Beam Radiation Therapy
G Grade
HSPC Hormone-Sensitive Prostate Cancer
LC Local Control
MFS Metastasis-Free Survival
mpMRI Multiparametric Magnetic Resonance Imaging
MDT Metastasis-Directed Therapies
OS Overall Survival
PSMA-PET Prostate-Specific Membrane Antigen Positron Emission Tomography
PTV Planning Target Volume
RFS Relapse-Free Survival
RP Post-operative Radiotherapy
s-SBRT Salvage Stereotactic Body Radiation Therapy